Parabilis Medicines Appoints Dr. Craig L. Tendler to Board
Biotechnology
Change of Management
IPO:
Jun 10, 2026
Industry:
PHARMACEUTICAL PREPARATIONS
Show Chart?
Load external content from TradingView!
*You can change or withdraw your consent at any time in the footer under Cookies.
Parabilis Medicines Appoints Dr. Craig L. Tendler to Board of Directors
CAMBRIDGE, Mass., USA - Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases by unlocking undruggable targets, announced the appointment of Craig L. Tendler, M.D., to its Board of Directors.
... Read on — Members only
About Parabilis Medicines, Inc.
We are a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. We leverage our proprietary platform to pioneer a novel therapeutic modality, Helicons, which are stabilized helical peptides engineered to bind and precisely modulate proteins that have long been beyond the reach of conventional medicines.
More PBLS News
Biotechnology
Daily overview of upcoming SPAC and IPO events – from initial announcement to definitive agreement and public listing.
Discover last week’s SPAC and IPO highlights, key trends, and market updates. Stay informed with SpacStar.